Pricing Log in Create free account

Parabilis Medicines, Inc. (PBLS) vs Xenon Pharmaceuticals Inc. (XENE)

Parabilis Medicines, Inc. and Xenon Pharmaceuticals Inc. are both Biotechnology companies. Parabilis Medicines, Inc. and Xenon Pharmaceuticals Inc. are of similar size ($3.7B and $3.4B). Across the 10 metrics below, Parabilis Medicines, Inc. leads on 6 and Xenon Pharmaceuticals Inc. on 4.

Valuation

Metric PBLS XENE Biotechnology median
P/E n/m n/m 10.26
P/S n/m 222.58 9.18
P/B 0.77 3.03 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA 1.79 n/m 0.65
EV/Sales n/m 169.19 8.98
Earnings yield (297.78%) (12.53%) (34.89%)
Free cash flow yield (14.78%) (8.98%) (24.52%)

Profitability

Metric PBLS XENE Biotechnology median
Gross margin — 28.40% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (43.62%) (50.12%)
Return on assets 0.00% (41.54%) (45.60%)
Return on invested capital 0.00% (88.54%) 0.00%

Growth

Metric PBLS XENE Biotechnology median
Revenue growth (TTM) — (8.15%) 6.26%
EPS growth (last fiscal year) (10.69%) (44.85%) 29.88%
Revenue growth, 5-year CAGR — 89.00% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric PBLS XENE Biotechnology median
Debt to equity 0.01 0.00 0.00
Current ratio 17.91 21.02 4.89
Net debt to EBITDA 0.09 1.48 1.01

Dividend

Metric PBLS XENE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PBLS XENE Biotechnology median
Market cap 3.44b 3.65b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack